Wockhardt's Imatinib Mesylate tablets are a generic version of Gleevec, marketed in USA and other countries by Novartis.

The company mainly benefited from the exclusivity opportunity for anti-cancer drug imatinib in the US.

The regulatory body has cut by nearly 30% the price of Imatinib, used to treat cancers and blood diseases, including different types of leu...

The company, which made windfall gains in the fourth quarter from sales of cancer drug imatinib in the US, said it will invest up to 9% of ...

Drug maker Sun Pharmaceuticals launched Imatinib Mesylate, the generic copy of anti-cancer drug Gleevec, in the US market enjoying 180 days...

Novartis, which owns patent for Glivec globally but excluding India, and Natco Pharma, whose generic version of drug was also listed on web...

Advocating for lower drug prices is a necessity to save the lives of patients who cannot afford them,” said a research report backed by the...

In a major relief for blood cancer patients, the state's health department is all set to provide Imatinib tablets ("magic bullet" tablets) ...

Novartis lost its case on technical grounds. It failed to establish that the drug’s new form was sufficiently patentable.

Novartis, however, said: "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment ...

The Indian subsidiary of Swiss drug maker Novartis is making a final attempt at getting a patent for its anti-cancer drug Imatinib with the...

The Madras High Court will hear on October 8, Novartis' objection to the appointment of S Chandrasekaran, former Controller General of the ...

Hearings in Novartis’ appeal against the rejection of patent for its anti-cancer drug Glivec have been suspended yet again, after the Madra...

Novartis has lost its challenge against the Indian government on the question of patent for incremental innovation, but its specific appeal...

HC dismisses a petition filed by Novartis, challenging the constitutional validity of the Sect 3 (d) of the patents (amendment) act 2005.

When Novartis AG was accused of jeopardising patients’ access to generic medicines in India last year, the Swiss drug giant thought it woul...

Following the rejection of its patent application for anti-cancer drug Glivec, Swiss pharmaceutical giant Novartis is not only challenging ...